Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 9/20 | 0.51 |
| ▸ | MAOB | P27338 | 9/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450985 | 0.96 | S1PR1 (0.52) | PLA2G4AMAOAMAOBS1PR1S1PR3 | |
| SCHEMBL947314 | 0.86 | FFAR1 (0.59) | MAOAMAOBS1PR1S1PR3PTPN1 | |
| SCHEMBL13617801 | 0.85 | MAOA (0.69) | MAOAMAOBFFAR1RAB9A | |
| SCHEMBL3904670 | 0.83 | MAOA (0.71) | MAOAMAOBRAB9A | |
| SCHEMBL3083583 | 0.81 | FFAR1 (0.60) | S1PR1S1PR3PTPN1HPGDFFAR1 | |
| SCHEMBL9819692 | 0.81 | MAOA (0.68) | MAOAMAOBPTPN1FFAR1RAB9A | |
| SCHEMBL9098252 | 0.80 | FFAR1 (0.59) | S1PR1S1PR3PTPN1HPGDFFAR1 | |
| SCHEMBL3843475 | 0.80 | FFAR1 (0.59) | S1PR1S1PR3PTPN1HPGDFFAR1 | |
| SCHEMBL7273053 | 0.80 | ALDH1A1 (0.54) | PLA2G4AHPGD | |
| SCHEMBL2233399 | 0.80 | HPGD (0.58) | S1PR1S1PR3PTPN1HPGDFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | PLA2G4A 296/4885MAOA 2130/4885MAOB 2098/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | PLA2G4A 322/4885MAOA 2174/4885MAOB 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.